Tag:
tivozanib
Latest Headlines
Latest Headlines
UPDATED: ASCO abstracts reveal added appeal for key cancer drug prospects
The avalanche of ASCO abstracts last night triggered a flurry of news reports about the most notable new data on experimental therapies to be revealed ahead of next month's big meeting in Chicago.
Aveo Pharma flunks Phase II lung cancer study
Aveo's share price slid a modest 30 cents, or 2.53%, to $11.77, as of 10:30 a.m. ET Wednesday.
Top 10 late-stage cancer drugs in 2012
Thousands of experimental meds are winding their way through various stages of clinical trials today, and the largest category among the contenders is cancer drugs.
Aveo on a hiring spree as it preps for the launch of tivozanib
The fast-growing developer tells The Boston Globe that it plans to hire 120 new staffers this year in preparation for the likely upcoming launch of tivozanib.
UPDATED: Aveo shares sink on weak PhIII face-off with Nexavar
Aiming at a regulatory filing for the experimental kidney cancer drug tivozanib later this year, Aveo Pharmaceuticals ( $AVEO ) unveiled a slate of late-stage data this morning designed to help build
Aveo inks $1.4B cancer drug deal, blueprints rapid expansion
Aveo Pharmaceuticals ( $AVEO ) has landed a rich, $1.4 billion development and commercialization pact with Astellas for its late-stage VEGF inhibitor tivozanib. Now in a Phase III head-to-head study
Biomarker can predict tivozanib resistance
Researchers believe there may be a way to predict which patients are more likely to respond to the experimental drug tivozanib. This is possible, said researchers from AVEO, because they have used a
